Brokerages expect Catalent Inc (NYSE:CTLT) to report sales of $723.04 million for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Catalent’s earnings, with estimates ranging from $713.40 million to $735.70 million. Catalent posted sales of $685.30 million in the same quarter last year, which suggests a positive year-over-year growth rate of 5.5%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, August 27th.
On average, analysts expect that Catalent will report full-year sales of $2.51 billion for the current year, with estimates ranging from $2.51 billion to $2.53 billion. For the next financial year, analysts forecast that the company will report sales of $2.86 billion, with estimates ranging from $2.69 billion to $2.94 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Catalent.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.49 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.07. Catalent had a return on equity of 16.78% and a net margin of 6.01%. The business had revenue of $617.50 million during the quarter, compared to analysts’ expectations of $644.88 million. During the same quarter in the prior year, the business earned $0.41 earnings per share. The company’s quarterly revenue was down 1.7% compared to the same quarter last year.
Catalent stock opened at $53.16 on Wednesday. Catalent has a 12 month low of $29.23 and a 12 month high of $54.10. The company has a debt-to-equity ratio of 1.31, a current ratio of 2.18 and a quick ratio of 1.71. The business’s 50 day moving average is $47.40. The stock has a market capitalization of $7.76 billion, a PE ratio of 33.43, a PEG ratio of 2.75 and a beta of 1.57.
In other news, Director Donald E. Morel, Jr. bought 10,000 shares of the stock in a transaction on Wednesday, May 15th. The shares were bought at an average price of $44.44 per share, with a total value of $444,400.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Peter L. Buzy bought 44,500 shares of the stock in a transaction on Wednesday, May 29th. The stock was purchased at an average cost of $45.13 per share, for a total transaction of $2,008,285.00. Following the acquisition, the insider now directly owns 44,500 shares of the company’s stock, valued at approximately $2,008,285. The disclosure for this purchase can be found here. Insiders have purchased 56,500 shares of company stock worth $2,542,845 in the last ninety days. 1.40% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC grew its holdings in Catalent by 17.6% in the first quarter. Janus Henderson Group PLC now owns 17,503,223 shares of the company’s stock valued at $710,456,000 after purchasing an additional 2,620,352 shares during the last quarter. BlackRock Inc. grew its holdings in Catalent by 7.9% in the first quarter. BlackRock Inc. now owns 13,918,974 shares of the company’s stock valued at $564,971,000 after purchasing an additional 1,023,315 shares during the last quarter. Vanguard Group Inc grew its holdings in Catalent by 9.4% in the third quarter. Vanguard Group Inc now owns 12,925,639 shares of the company’s stock valued at $588,763,000 after purchasing an additional 1,110,779 shares during the last quarter. Champlain Investment Partners LLC grew its holdings in Catalent by 1.9% in the first quarter. Champlain Investment Partners LLC now owns 3,913,500 shares of the company’s stock valued at $158,849,000 after purchasing an additional 74,670 shares during the last quarter. Finally, Brown Advisory Inc. grew its holdings in Catalent by 11.0% in the fourth quarter. Brown Advisory Inc. now owns 2,890,711 shares of the company’s stock valued at $90,132,000 after purchasing an additional 285,768 shares during the last quarter. 96.85% of the stock is currently owned by institutional investors.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Recommended Story: How to start trading in the forex market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.